The drugs in ocular treatment are being resisted by the mucin in eyes to reach the targeted cells. Therefore, precise medication should be adopted in order to enhance the effective ocular treatment.
Usually, the most common therapy for drug issue in ocular conditions is eye drops, also known as topical. However, the drug is not able to get into the targeted cells due to mucin. Mucin is the natural substance that is found in tears, which protects the eyes from external hazards. Whenever some external trash enters the eyes, mucin plays a vital role in cleaning eyes and protecting them from these things.
Whenever certain ophthalmological drugs are put in the eyes, mucin gets interacted with this drug delivery system (DSS). Mucin gets exposed to the lipoplex, molecule used in this drug; it hinders the absorption of the drug and prevents them to reach the targeted cells.
So, the research was carried out to resist the action of mucin against drugs in eyes. The group of researchers was formed by international alliance of the University of Pennsylvania’s Scheie Eye Institute, Sbarro Institute of Cancer Research and Molecular Medicine at Temple University, and co-authors at several universities in Italy. The researchers attempted to come across the protein called as fibronectin (FBN) and the other is a tripeptide of amino acids consisting of valine, glycine and aspartate (VGA). Both of these were so effective at dressing the lipoplex up and resisted the mucin coating and binding. This allows the drug to directly get and absorb into the targeted corneal epithelial cells.
Giacamina Massaro, MD, of the Scheie Eye Institute, commented that the drug is resisted by the complex of lipids, proteins, mucous and fluids, which keeps the eyes clean. That is why it is important that the drugs should possess the ability to break through these barriers in order to reach targeted tissues and have effective treatment.